



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/989,758	1 1/20/2001	Todd R. Golub	WIBL-POL-579	9648
7590 06/20/2005			EXAMINER	
Lisa M. Treannie, Esq.			FREDMAN, JEFFREY NORMAN	
	ROOK, SMITH & REY	ART UNIT	PAPER NUMBER	
530 Virginia Ro	oad	AKI UNII	PAPER NOMBER	
P.O. Box 9133			1637	
Concord, MA 01742-9133			DATE MAILED: 06/20/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application N	o. Applicant(s)	
		09/989,758	GOLUB ET AL.	
	Office Action Summary	Examiner	Art Unit	
		Jeffrey Fredma	L	
Period 1	The MAILING DATE of this communior Reply	ication appears on the cov	ver sheet with the correspondence a	address
THE - Extra after - If th - If N - Fail	HORTENED STATUTORY PERIOD F. MAILING DATE OF THIS COMMUNI ensions of time may be available under the provisions or SIX (6) MONTHS from the mailing date of this comm he period for reply specified above is less than thirty (3) of period for reply is specified above, the maximum stature to reply within the set or extended period for reply or reply received by the Office later than three months a hed patent term adjustment. See 37 CFR 1.704(b).	CATION. of 37 CFR 1.136(a). In no event, he nunication. 0) days, a reply within the statutory eatutory period will apply and will expivall, by statute, cause the application	owever, may a reply be timely filed  minimum of thirty (30) days will be considered tim  ire SIX (6) MONTHS from the mailing date of this in to become ABANDONED (35 U.S.C. § 133).	
Status				
1)[🛛	Responsive to communication(s) file	ed on <i>25 May 2005</i>		
تطارا [_(2a		2b)⊠ This action is non-f	inal	
3)□		<i>'</i> —		he merits is
∟ر≎	closed in accordance with the practi	,	· ·	
	·	ZZ parto quajfo	,	
Disposi	tion of Claims			
4)⊠	Claim(s) <u>1-5,8,15-20 and 37-40</u> is/ar	e pending in the applicat	on.	
	4a) Of the above claim(s) is/a	re withdrawn from consid	eration.	
5)	Claim(s) is/are allowed.			
6)[				
7)	Claim(s) is/are objected to.			
8)🖂	Claim(s) <u>1-5,8,15-20 and 37-40</u> are	subject to restriction and/	or election requirement.	
Applica <sup>·</sup>	tion Papers			
9)[	The specification is objected to by the	e Examiner.		
-	The drawing(s) filed on is/are:		biected to by the Examiner.	
,—,	Applicant may not request that any object			
	Replacement drawing sheet(s) including		•	CFR 1.121(d).
11)	The oath or declaration is objected to		• • • •	• •
	under 35 U.S.C. § 119			
_	_			
• -	Acknowledgment is made of a claim	tor foreign priority under	35 U.S.C. § 119(a)-(d) or (f).	
a)	) ☐ All b) ☐ Some * c) ☐ None of:			
	1.☐ Certified copies of the priority			
	<u> </u>		ceived in Application No	
	3. Copies of the certified copies	· ·		al Stage
	application from the Internatio		, ,,	
*	See the attached detailed Office actio	n tor a list of the certified	copies not received.	
Attachme	` '	۰, ۲	7	
411 141 "	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (P		Interview Summary (PTO-413) Paper No(s)/Mail Date	
2) 🔲 Noti	rmation Disclosure Statement(s) (PTO-1449 or	PTO/SB/08) 5) L	Notice of Informal Patent Application (P Other:	TO-152)

Application/Control Number: 09/989,758 Page 2

Art Unit: 1637

## **DETAILED ACTION**

## Election/Restrictions

1. Claims 1-5, 8, 15-20 and 37-40 are generic to a plurality of disclosed patentably distinct species comprising the genes shown in figures 1, 2A, 2B (excluding the P16 gene), 3A, 3B, 4A and 4B excluding cathepsin B, cyclin B1 and CD3 epsilon.

2. The claims prior to the current amendment were generic to any genes whatsoever, and the prior art of Alizadeh enabled various sets of genes for the analysis of lymphoma samples. The current claims are limited to the specific genes listed in the identified figures minus the excluded genes. These claims are now significantly different and have immense search burdens which are now imposed upon the examination.

Therefore, Applicant is required under 35 U.S.C. 121 to elect a single pair of informative genes for analysis, even though this requirement is traversed. In addition to identifying the two genes, Applicant should note in which tables these informative genes are found as well as the Genbank accession number, if any, for the two informative genes selected. If the two genes selected by Applicant are novel and unobvious, the search will be extended by the examiner to select additional genes. Further, Applicant should be aware that the selected genes must comply with the enablement requirements of 35 U.S.C. 112, first paragraph, an issue not previously significant given the enabling disclosures in the prior art for the generic claim such as Alizadeh. Finally, Applicant should note that if new prior art or new enablement rejections, necessitated by

this significant amendment, are applied following the election, that action will be made Final.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

- Applicant is advised that the reply to this requirement to be complete must 3. include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- Applicant is reminded that upon the cancellation of claims to a non-elected 4. invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Fredman whose telephone number is (571)272-0742. The examiner can normally be reached on 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571)272-0782. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 09/989,758 Page 4

Art Unit: 1637

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jeffrey Fredman Primary Examiner Art Unit 1637